Clinical Trial Update: 18F-DTBZ PET and Multi-modal MRI in the Patients With Vascular Parkinsonism [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating 18F-DTBZ PET and multi-modal MRI in patients with vascular parkinsonism has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vascular Parkinsonism

Drugs mentioned

• 18F-DTBZ (fluorine-18 labeled dihydrotetrabenazine)

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Vascular Parkinsonism | Phase 2 | Status: COMPLETED